LPL Financial
AKBA icon

LPL Financial’s Akebia Therapeutics AKBA Stock Holding History

LPL Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
95,516
+10,000
+12% +$11.9K ﹤0.01% 5903
2026
Q1 		$119K Buy
85,516
+24,313
+40% +$33.4K ﹤0.01% 5641
2025
Q4 		$98.5K Buy
61,203
+11,435
+23% +$23.9K ﹤0.01% 5596
2025
Q3 		$136K Sell
49,768
-4,100
-8% -$13.6K ﹤0.01% 5445
2025
Q2 		$196K Buy
53,868
+2,100
+4% +$5.77K ﹤0.01% 5098
2025
Q1 		$99.4K Buy
51,768
+9,130
+21% +$18.6K ﹤0.01% 5043
2024
Q4 		$81K Sell
42,638
-1,497
-3% -$2.6K ﹤0.01% 5031
2024
Q3 		$58.3K Sell
44,135
-13,897
-24% -$18.6K ﹤0.01% 4978
2024
Q2 		$59.2K Buy
58,032
+40,187
+225% +$49.7K ﹤0.01% 4822
2024
Q1 		$32.7K Buy
+17,845
New +$28.5K ﹤0.01% 4802
2023
Q2 		– Sell
-28,596
Closed -$16K – 4591
2023
Q1 		$16K Buy
+28,596
New +$21.8K ﹤0.01% 4430
2020
Q3 		– Sell
-35,294
Closed -$479K – 3552
2020
Q2 		$479K Sell
35,294
-991
-3% -$10.3K ﹤0.01% 2426
2020
Q1 		$275K Buy
36,285
+1,526
+4% +$11.9K ﹤0.01% 2560
2019
Q4 		$220K Buy
34,759
+2,234
+7% +$10.6K ﹤0.01% 3026
2019
Q3 		$127K Sell
32,525
-1,023
-3% -$4.38K ﹤0.01% 3120
2019
Q2 		$162K Sell
33,548
-440
-1% -$2.5K ﹤0.01% 3078
2019
Q1 		$278K Buy
33,988
+5,725
+20% +$39.3K ﹤0.01% 2707
2018
Q4 		$156K Buy
28,263
+1,500
+6% +$11.7K ﹤0.01% 2883
2018
Q3 		$236K Buy
26,763
+7,314
+38% +$65.4K ﹤0.01% 2868
2018
Q2 		$194K Buy
+19,449
New +$195K ﹤0.01% 2989
2018
Q1 		– Sell
-23,559
Closed -$350K – 3179
2017
Q4 		$350K Buy
+23,559
New +$391K ﹤0.01% 2360
2017
Q2 		– Sell
-10,062
Closed -$90K – 2800
2017
Q1 		$90K Sell
10,062
-270
-3% -$2.64K ﹤0.01% 2624
2016
Q4 		$108K Sell
10,332
-164
-2% -$1.41K ﹤0.01% 2582
2016
Q3 		$94K Buy
+10,496
New +$89.2K ﹤0.01% 2542

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LPL Financial's AKBA Position: Q2 2026 in Review

LPL Financial increased its Akebia Therapeutics (AKBA) stake by 12% in Q2 2026, buying an estimated $11.9K and bringing the position to 95,516 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #5903.

LPL Financial first reported a position in AKBA in Q3 2016 and has held it in 24 quarters since. The position peaked at $479K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • LPL Financial held 95,516 shares of Akebia Therapeutics worth $109K as of Q2 2026.
  • LPL Financial bought 10,000 Akebia Therapeutics shares in Q2 2026, an estimated $11.9K.
  • Akebia Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5903 holding.
  • LPL Financial first reported a position in Akebia Therapeutics in Q3 2016 and has held it in 24 quarters since.
  • LPL Financial's Akebia Therapeutics position peaked at $479K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.